Provident Financial Services: Akeso's Ivonescimab Approved, Advancing Cancer Treatment in China
- Akeso's ivonescimab receives updated approval in China for treating advanced non-small cell lung cancer patients.
- The drug shows significant improvements in survival rates and progression-free survival for previously treated patients.
- Ivonescimab's inclusion in China's National Reimbursement Drug List enhances patient access to this innovative treatment option.
Advancements in Cancer Treatment: Akeso's Ivonescimab Receives Updated Approval in China
Akeso, Inc. announces a significant milestone with the recent approval from the National Medical Products Administration (NMPA) in China for an updated label for its PD-1/VEGF bispecific antibody, ivonescimab. This approval arises from the final analysis of the pivotal AK112-301/HARMONi-A study, which reveals promising results for patients suffering from locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) who have previously undergone treatment with EGFR-TKI therapies. The study showcases substantial enhancements in both progression-free survival (PFS) and overall survival (OS) for this challenging patient demographic, marking a critical advancement in immunotherapy options available in China.
The HARMONi-A trial stands out as the first Phase III immunotherapy study to demonstrate significant improvements in its co-primary endpoints within this specific patient population. The final analysis, which encompasses a median follow-up of 32.5 months, indicates that patients receiving ivonescimab experience a 26% reduction in the risk of death (OS HR=0.74, P=0.019) and a remarkable 54% reduction in the risk of disease progression or death (PFS HR=0.46, P＜0.001). Moreover, the median PFS extends from 4.8 months to 7.1 months, offering hope for improved patient outcomes. Importantly, the long-term safety profile of ivonescimab remains favorable, with no new safety signals identified, reinforcing its viability as a treatment option.
Initially granted approval in May 2024, ivonescimab has also been included in China's National Reimbursement Drug List (NRDL) as of November 2024, effective January 1, 2025. This inclusion not only broadens access for patients but also highlights the drug's significance in the treatment landscape. Furthermore, the approval of ivonescimab for first-line treatment of PD-L1-positive NSCLC in April 2025, along with its addition to the NRDL in early 2026, positions it as a highly effective, well-tolerated, and durable chemotherapy-free option for patients in China, paving the way for enhanced therapeutic strategies in the management of lung cancer.
In related news, the growing focus on innovative cancer therapies like ivonescimab underscores the urgent need for advancements in treatment options for patients with limited responses to traditional therapies. As companies like Akeso continue to push the boundaries of immunotherapy, the healthcare industry anticipates further breakthroughs that could redefine lung cancer management. The commitment to developing effective and accessible treatments highlights the evolving landscape of oncology, which increasingly favors personalized medicine approaches.